Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C5H7NO3 |
Molecular Weight | 129.114 |
Optical Activity | ( - ) |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)[C@@H]1CCC(=O)N1
InChI
InChIKey=ODHCTXKNWHHXJC-VKHMYHEASA-N
InChI=1S/C5H7NO3/c7-4-2-1-3(6-4)5(8)9/h3H,1-2H2,(H,6,7)(H,8,9)/t3-/m0/s1
Molecular Formula | C5H7NO3 |
Molecular Weight | 129.114 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.currentscience.ac.in/Volumes/102/02/0288.pdfhttps://www.drugs.com/otc/121041/cleansing-foaming-gel-acne-pro-skin.html | https://www.ncbi.nlm.nih.gov/pubmed/25727335 | https://www.ncbi.nlm.nih.gov/pubmed/21834944 | https://www.ulprospector.com/en/na/PersonalCare/Detail/6637/223524/EcoCare-Zinclean | http://www.scalp-health.com/zinc-pca.htmCurator's Comment: description was created based on several sources, including
http://www.cir-safety.org/sites/default/files/pca.pdf
Sources: http://www.currentscience.ac.in/Volumes/102/02/0288.pdfhttps://www.drugs.com/otc/121041/cleansing-foaming-gel-acne-pro-skin.html | https://www.ncbi.nlm.nih.gov/pubmed/25727335 | https://www.ncbi.nlm.nih.gov/pubmed/21834944 | https://www.ulprospector.com/en/na/PersonalCare/Detail/6637/223524/EcoCare-Zinclean | http://www.scalp-health.com/zinc-pca.htm
Curator's Comment: description was created based on several sources, including
http://www.cir-safety.org/sites/default/files/pca.pdf
Zinc Pidolate (Zinc PCA) is a topical skin product with purifying, astingent, anti-inflammatory, antiseptic activity. It has long been used as a cosmetic ingredient, because of its astringent and anti-microbial properties. Zinc Pidolate has also being shown to be effective against halitosis. Zinc PCA prevents the UV-induced MMP-1 production in vitro by suppressing the activation of AP-1. Zinc PCA was also able to enhance type I collagen synthesis in NHDFs, by increasing the expression of the mRNA encoding the ascorbic acid transporter SVCT2 in non-UV irradiated
NHDFs, which suggests its promising effect against not only photoaged skin but also for the simple atrophic change of intrinsic skin ageing. Zinc PCA is able to suppress sebum secretion by inhibiting 5-α reductase in hyperseborrhea, to suppress body odor by forming zinc salts with short-chain fatty acids, to suppress wrinkles by inhibiting AP-1 to and inhibit bacterial growth including acne related Propionibacterium acnes.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3271 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21834944 |
|||
Target ID: P02452|||Q15176|||Q9UML6 Gene ID: 1277.0 Gene Symbol: COL1A1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/21834944 |
|||
Target ID: CHEMBL2111421 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21834944 |
|||
Target ID: CHEMBL612639 |
|||
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | CLEANSING FOAMING GEL ACNE PRO SKIN- zinc pidolate gel Approved UseLange Gel will turn into foam, during application. It will cleanse skin thoroughly without any dryness effect, in order to avoid hyperseboohea phenomenon, a main cause of acne. Launch Date2012 |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | EcoCare™ Zinclean Approved UseUse in anti-dandruff shampoos |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
The X-ray crystal structure of pyrrolidone-carboxylate peptidase from hyperthermophilic archaea Pyrococcus horikoshii. | 2002 |
|
Expression and prognostic significance of lysozyme in male breast cancer. | 2002 |
|
Continuous spectrometric assays for glutaminyl cyclase activity. | 2002 Apr 1 |
|
Spectrophotometric assays for L-lysine alpha-oxidase and gamma-glutamylamine cyclotransferase. | 2002 Apr 15 |
|
CLAC: a novel Alzheimer amyloid plaque component derived from a transmembrane precursor, CLAC-P/collagen type XXV. | 2002 Apr 2 |
|
Complete structure of an increasing capillary permeability protein (ICPP) purified from Vipera lebetina venom. ICPP is angiogenic via vascular endothelial growth factor receptor signalling. | 2002 Aug 16 |
|
Generation of amyloid beta peptide with pyroglutamate at position 3 in primary cortical neurons. | 2002 Jul 12 |
|
Allatostatins of the tiger prawn, Penaeus monodon (Crustacea: Penaeidea). | 2002 Jun |
|
Stereoselective total syntheses of the racemic form and the natural enantiomer of the marine alkaloid lepadiformine via a novel N-acyliminium ion/allylsilane spirocyclization strategy. | 2002 Jun 14 |
|
Two novel antifungal peptides distinct with a five-disulfide motif from the bark of Eucommia ulmoides Oliv. | 2002 Jun 19 |
|
Pseudopeptide foldamers: the homo-oligomers of pyroglutamic acid. | 2002 Jun 3 |
|
[Effect of a drug composition containing pyroglutamic acid and pyrrolidone on the cerebral circulation]. | 2002 May-Jun |
|
Fluorometric assay using naphthylamide substrates for assessing novel venom peptidase activities. | 2002 Nov |
|
Synthesis and preliminary evaluation of trans-3,4-conformationally-restricted glutamate and pyroglutamate analogues as novel EAAT2 inhibitors. | 2002 Nov 4 |
|
Methacrylate derivatives incorporating pyroglutamic acid. | 2002 Nov-Dec |
|
Production of pyroglutamic acid by thermophilic lactic acid bacteria in hard-cooked mini-cheeses. | 2002 Oct |
|
Heterologous expression and characterization of human glutaminyl cyclase: evidence for a disulfide bond with importance for catalytic activity. | 2002 Sep 3 |
|
Stereoselective synthesis of dipeptide beta-turn mimetics: 7-benzyl and 8-phenyl substituted azabicyclo[4.3.0]nonane amino acid esters. | 2002 Sep 6 |
|
Characterization and sequence of tomato 2S seed albumin: a storage protein with sequence similarities to the fruit lectin. | 2003 Apr |
|
Pigment-epithelium-derived factor (PEDF) occurs at a physiologically relevant concentration in human blood: purification and characterization. | 2003 Aug 15 |
|
Refolding of amphioxus insulin-like peptide: implications of a bifurcating evolution of the different folding behavior of insulin and insulin-like growth factor 1. | 2003 Aug 19 |
|
Beta-lactams as versatile synthons for homochiral ibotenate analogues with potential for activity at glutamate receptors. | 2003 Aug 7 |
|
Solution structure of the cytotoxic RNase 4 from oocytes of bullfrog Rana catesbeiana. | 2003 Feb 28 |
|
Isolation and identification of indigestible pyroglutamyl peptides in an enzymatic hydrolysate of wheat gluten prepared on an industrial scale. | 2003 Jan 1 |
|
[Neuroprotective properties of pyroglutamic acid in combination with pyrrolidone]. | 2003 Jan-Feb |
|
Characterization of a new bradykinin-potentiating peptide (TmF) from Trimeresurus mucrosquamatus. | 2003 Jul |
|
Pyrrolidinones derived from (S)-pyroglutamic acid: penmacric acid and analogues. | 2003 Jul 7 |
|
2,5-Disubstituted pyrrolidines: versatile regioselective and diastereoselective synthesis by enamine reduction and subsequent alkylation. | 2003 Jun 7 |
|
Reinvestigation of the proposed folding and self-association of the Neuropeptide Head Activator. | 2003 Mar |
|
[Evolution of the neuroprotection concept]. | 2003 Mar-Apr |
|
[Oleyl pyroglutamate for use as transdermal enhancer and its enhancing mechanism]. | 2003 May |
|
Proinsulin C-peptide and its C-terminal pentapeptide: degradation in human serum and Schiff base formation with subsequent CO2 incorporation. | 2003 May |
|
[Characteristics of pyrrolidone pharmacokinetics in rats]. | 2003 Nov-Dec |
|
Structural characterization of native mouse zona pellucida proteins using mass spectrometry. | 2003 Sep 5 |
|
Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions. | 2004 Apr 9 |
|
Glutamine in commercial liquid nutritional products. | 2004 Aug 11 |
|
Toward the synthesis of pyroglutamate lauroyl ester: biocatalysis versus chemical catalysis. | 2004 Feb |
|
Stabilization of peptide guinea pig myelin basic protein 72-85 by N-terminal acetylation-implications for immunological studies. | 2004 Feb |
|
Human glutaminyl cyclase and bacterial zinc aminopeptidase share a common fold and active site. | 2004 Feb 10 |
|
Unexplained metabolic acidosis in critically ill patients: the role of pyroglutamic acid. | 2004 Mar |
|
Synthesis of (2S,3R)-[3',3',3'-2H3]-valine and (2S,3S)-4-fluorovaline. | 2004 May 7 |
|
The development of a higher throughput reactive intermediate screening assay incorporating micro-bore liquid chromatography-micro-electrospray ionization-tandem mass spectrometry and glutathione ethyl ester as an in vitro conjugating agent. | 2004 Sep 21 |
|
The computer modelling of human TRH receptor, TRH and TRH-like peptides. | 2005 |
|
Formation of extracellular glutamate from glutamine: exclusion of pyroglutamate as an intermediate. | 2005 Aug 2 |
|
Stereoselective synthesis of conformationally constrained omega-amino acid analogues from pyroglutamic acid. | 2005 Aug 7 |
|
Physiological and pathological aspects of GSH metabolism. | 2005 Feb |
|
CLPM: a cross-linked peptide mapping algorithm for mass spectrometric analysis. | 2005 Jul 15 |
|
Total synthesis of pinnamine and anatoxin-a via a common intermediate. A caveat on the anatoxin-a endgame. | 2005 Jul 8 |
|
Bromophenols coupled with derivatives of amino acids and nucleosides from the red alga Rhodomela confervoides. | 2005 May |
|
Synthesis of 1,3-dioxo-hexahydropyrido[1,2-c][1,3]diazepine carboxylates, a new bicyclic skeleton formed by ring expansion-RCM methodology. | 2005 Sep 21 |
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 07:52:53 GMT 2025
by
admin
on
Wed Apr 02 07:52:53 GMT 2025
|
Record UNII |
SZB83O1W42
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LOINC |
75089-3
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
||
|
LOINC |
13700-0
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
||
|
DSLD |
2731 (Number of products:44)
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
||
|
NCI_THESAURUS |
C29703
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
||
|
LOINC |
29872-9
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
||
|
LOINC |
29522-0
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
||
|
LOINC |
53394-3
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
||
|
LOINC |
53232-5
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
||
|
LOINC |
43633-7
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
||
|
EU-Orphan Drug |
EU/3/16/1673
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
760414
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
PRIMARY | |||
|
DTXSID6046260
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
PRIMARY | |||
|
143034
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
PRIMARY | |||
|
16010
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
PRIMARY | |||
|
155060
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
PRIMARY | RxNorm | ||
|
PYROGLUTAMIC ACID
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
PRIMARY | |||
|
58402
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
PRIMARY | |||
|
1589029
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
PRIMARY | |||
|
18183
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
PRIMARY | |||
|
m9383
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
PRIMARY | Merck Index | ||
|
4079
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
PRIMARY | |||
|
98-79-3
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
PRIMARY | |||
|
30652
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
PRIMARY | |||
|
SZB83O1W42
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
PRIMARY | |||
|
7405
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
PRIMARY | |||
|
DB03088
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
PRIMARY | |||
|
100000081944
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
PRIMARY | |||
|
202-700-3
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
PRIMARY | |||
|
SUB09825MIG
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
PRIMARY | |||
|
57606
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
PRIMARY | |||
|
C82933
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
PRIMARY | |||
|
SZB83O1W42
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
PRIMARY | |||
|
CHEMBL284718
Created by
admin on Wed Apr 02 07:52:53 GMT 2025 , Edited by admin on Wed Apr 02 07:52:53 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|